BiotechTube

RotaTeq (V260) + IPV

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Conditions

Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Trial Timeline

Aug 25, 2020 → May 8, 2021

NCT ID
NCT04481191

About RotaTeq (V260) + IPV

RotaTeq (V260) + IPV is a phase 3 stage product being developed by Merck for Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9. The current trial status is completed. This product is registered under clinical trial identifier NCT04481191. Target conditions include Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04481191Phase 3Completed

Competing Products

20 competing products in Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

See all competitors
ProductCompanyStageHype Score
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
77
MifepristoneEli LillyPhase 2
52
EXANTAAstraZenecaPhase 2
52
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
23
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
77
Esomeprazole + PlaceboAstraZenecaPhase 3
77
PCV15MerckPre-clinical
23
RaltegravirMerckApproved
85
V501MerckPhase 3
77
ZostavaxMerckPhase 3
77
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
77
Letermovir + PlaceboMerckPhase 3
77
Meningococcal C conjugate vaccineNovartisApproved
85
Enteric-coated mycophenolate sodiumNovartisPhase 3
77
Meningococcal C conjugate vaccineNovartisApproved
85
rMenB+OMV NZNovartisPhase 3
77
Enteric-Coated Mycophenolate SodiumNovartisPhase 3
77
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5mlNovartisPhase 3
77
Meningococcal C Conjugate VaccineNovartisPhase 3
77
MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation) + MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation) + MenACWY PS (MenACWY-CRM, polysaccharide vaccine) + HBV (Hepatitis B vaccine) + Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197) + MMR (Measles, Mumps and Rubella vaccine) + DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine) + Menjugate (Men C conjugated vaccine)NovartisPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85